J Am Coll Cardiol. Both rare and common variants in PCSK9 influence plasma low-density lipoprotein cholesterol level in American Indians. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Google Scholar. J Cardiol. 2017;376:41–51. Mutations in other genes can also cause inherited high cholesterol. J Am Coll Cardiol. -, Atherosclerosis. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. Catherine Boileau. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. J Lipid Res. •• Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Article Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. 2015;372:1500–9. Subscription will auto renew annually. 2017;376:1527–39. The evolution of research on PCSK9, starting from the discovery of the first set of mutations in PCSK9 in FH in 2003, is an amazing example of successful translational research. REPATHA (evolocumab) injection, for subcutaneous use. Yamamoto T, Harada-Shiba M, Nakatani M, Wada S, Yasuhara H, Narukawa K, et al. 2004;65:419–22. Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, et al. 2010;55:2833–42. Tax calculation will be finalised during checkout. 2020 Feb 21;295(8):2285-2298. doi: 10.1074/jbc.RA119.010221. The LDLR gene provides instructions for making a protein called a low-density lipoprotein receptor. Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, et al. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. Genet. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. Mol Ther Nucleic Acids. Stein EA, Kasichayanula S, Turner T, Lee J. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. Keywords: Epub 2016 Jul 12. Preiss D, Baigent C. Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? 2015;36:1186–94. 2015;169:906–15. J Am Coll Cardiol. 2005;102:5374–9. Article 2007;193:445–8. Varret M, Rabès JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, et al. Part of Springer Nature. Humphries SE, Neely RDG, Whittall RA, Troutt JS, Konrad RJ, Scartezini M, et al. 2007;14:413–9. Epub 2015 Sep 30. Nat Struct Mol Biol. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. Sanger sequencing was used to confirm the … 2017;38(32):2499–507. 2020 Apr 2;9(4):296. doi: 10.3390/antiox9040296. Familial hypercholesterolemia (FH, OMIM 143890) is an inherited disorder of lipoprotein metabolism, ... Certain mutations in PCSK9 lead to hypercholesterolemia, while other mutations can cause hypocholesterolemia, a situation comparable to that of APOB , . Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, et al. This work was supported by a grant from the Fondation Leducq (FLQ no. PCSK9 Mutations and Familial Hypercholesterolemia Rare causes of familial hypercholesterolemia have been associated with gain-of-function mutations in the gene (PCSK9) encoding proprotein convertase subtilisin/kexin type 9. Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Circulation. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. 1999;64:1378–87. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. PCSK9 Mutations and Familial Hypercholesterolemia. 2005;366:1267–78. 2014;63:2541–8. Lancet Diabetes Endocrinol. van Poelgeest EP, Hodges MR, Moerland M, Tessier Y, Levin AA, Persson R, et al. N Engl J Med. 2014;63:2531–40. 2009;120:163-73 2012;366:1108–18. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Lipids Health Dis. 2008;283:31791–801. Recent findings: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Lancet Lond Engl. 2008;358:2299–300. BMC Med. Am J Hum Genet. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. | Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.